X0206 3 2013-05-21 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001198321 CHAMPSI FARAH ONE EMBARCADERO CENTER 37TH FLOOR SAN FRANCISCO CA 94111 1 0 0 0 Series B Convertible Preferred Stock Common Stock 42260 I Alta BioPharma Partners III GmbH & Co. Beteiligungs KG Series B Convertible Preferred Stock Common Stock 629255 I Alta BioPharma Partners III, L.P. Series B Convertible Preferred Stock Common Stock 15507 I Alta Embarcadero BioPharma Partners III, LLC Series C Convertible Preferred Stock Common Stock 28255 I Alta BioPharma Partners III GmbH & Co. Beteiligungs KG Series C Convertible Preferred Stock Common Stock 420738 I Alta BioPharma Partners III, L.P. Series C Convertible Preferred Stock Common Stock 10368 I Alta Embarcadero BioPharma Partners III, LLC Series D Convertible Preferred Stock Common Stock 4447 I Alta BioPharma Partners III GmbH & Co. Beteiligungs KG Series D Convertible Preferred Stock Common Stock 66221 I Alta BioPharma Partners III, L.P. Series D Convertible Preferred Stock Common Stock 1632 I Alta Embarcadero BioPharma Partners III, LLC The Series B Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series B Preferred Stock, for no additional consideration. The shares do not have an expiration date. Alta Partners III, Inc. provides investment advisory services to Alta BioPharma Partners III, L.P., Alta BioPharma Partners III GmbH & Co. Beteiligungs KG and Alta Embarcadero BioPharma Partners III, LLC (collectively, the Alta Funds). The directors of Alta BioPharma Management III, LLC, which is the general partner of Alta BioPharma Partners III, L.P., the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, and the manager of Alta Embarcadero BioPharma Partners III, LLC, exercise sole dispositive and voting power over the securities owned by the Alta Funds. Farah Champsi, a director of Alta BioPharma Management III, LLC and a manager of Alta Embarcadero BioPharma Partners III, LLC may be deemed to beneficially own the securities, and disclaims beneficial ownership of the shares identified in this footnote except to the extent of her respective proportionate pecuniary interest in such shares. The Series C Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series C Preferred Stock, for no additional consideration. The Series D Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series D Preferred Stock, for no additional consideration. /s/ Sally A. Kay, as attorney-in-fact 2013-05-21